Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

178

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Dulaglutide, Semaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 70,000 participants
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Intracranial Hypertension (IIH)
Interventions: Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more

Conditions: Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
Interventions: Tirzepatide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Obesity and Overweight, Binge Eating Disorder
Interventions: Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection); Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 39
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 35 more

Conditions: MASLD, Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: Bariatric Surgery, Semaglutide, Tirzepatide; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions: Discontinuation and Reinitiation of Tirzepatide; Other
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
Interventions: Tirzepatide, Lifestyle toolkit; Drug · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • Scarborough, Maine

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Medical Device Usage and Evaluation, Tirzepatide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas

About this Tirzepatide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Tirzepatide clinical trials

Filter and sort this therapy

Live official records

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Tirzepatide in Idiopathic Intracranial Hypertension Trial

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

GLP-1R Actions on Muscle and the Skeleton

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

About this Tirzepatide clinical trials directory page